AC
BLTE

AXQ Capital’s Belite Bio BLTE Stock Holding History

AXQ Capital’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,372
Closed -$378K – 1019
2026
Q1 		$378K Buy
+2,372
New +$399K 0.05% 511

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AXQ Capital's BLTE Position: Q2 2026 in Review

AXQ Capital sold out of Belite Bio (BLTE) in Q2 2026, closing a stake of 2,372 shares — an estimated $378K sold.

AXQ Capital first reported a position in BLTE in Q1 2026 and held it in 1 quarter. The position peaked at $378K in Q1 2026. 81 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • AXQ Capital reported no remaining Belite Bio position as of Q2 2026 after selling out during the quarter.
  • AXQ Capital sold 2,372 Belite Bio shares in Q2 2026, an estimated $378K.
  • AXQ Capital first reported a position in Belite Bio in Q1 2026 and held it in 1 quarter.
  • AXQ Capital's Belite Bio position peaked at $378K in Q1 2026.
  • 81 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.